$0.000
-0.000 (-100.00%)At close
PBM News
PBM Events
Selling Stockholders Plan to Sell 1.15M Common Shares
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.15M common shares. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Psyence BioMed to Visit U.S. to Promote Psychedelic Research
Psyence BioMed announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives. The visit follows recent U.S. policy developments supporting increased research collaboration, regulatory review pathways, and clinical investigation involving psychedelic compounds, including ibogaine. The purpose of the Company's upcoming U.S. engagement initiative is to educate and inform stakeholders on the complexity, regulatory considerations, and scientific infrastructure required to manufacture pharmaceutical-grade ibogaine under Good Manufacturing Practice standards suitable for regulated clinical research. "We believe global interest in ibogaine research continues to accelerate, particularly as policymakers, researchers, and healthcare institutions explore innovative approaches to serious mental health conditions," said Jody Aufrichtig, CEO of Psyence BioMed. "Our objective during this visit is to contribute constructively to those conversations by sharing our expertise and helping stakeholders better understand the highly specialized process required to produce compliant pharmaceutical-grade ibogaine suitable for regulated research environments."
Major Averages Decline Amid Escalating Tensions with Iran
The major averages closed fractionally lower as escalating tensions with Iran, including the seizure of an Iranian-flagged cargo ship and renewed threats from President Trump, raised concerns ahead of an expiring ceasefire. Iran's refusal to participate in peace talks further heightened geopolitical uncertainty and weighed on market sentiment, though the pullback was fairly muted. Of note, Trump said in a phone interview with Bloomberg that it is "highly unlikely" the two week ceasefire with Iran will be extended if a deal is not reached before it ends on Wednesday.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:QXOTopBuildfor $17B in a cash and stock transactionEli LillyKelonia Therapeutics, with Kelonia to receive up to $7B in cashAmerican Airlinessaid it isin any merger talks with United AirlinesAST SpaceMobileslipped after Blue Origin's flagship New Glenn rocket failed to place one of its satellitesPresident Trump signed an executive order toto the substances used outside the U.S to treat post-traumatic stress disorder2. WALL STREET CALLS:Wells FargoBiogento Overweight on pipeline outside Alzheimer'sBarclaysAvis Budgetto sell after "sharp short squeeze"Ulta Beautyto Buy at JefferiesMizuhoQorvoto Underperform on handset weaknessOktato Overweight at Barclays3. AROUND THE WEB:A tornado damaged part of Rivian's (RIVN) central Illinois plant over the weekend, CNBC reportsJersey Mike's Subs, Blackstone-backedsandwich chain with more than 3,000 locations, submitted a confidential filing with the U.S. Securities and Exchange Commission for its initial public offering, Bloomberg saysThe family that owns Brown-Forman, the maker of Jack Daniel's whiskey, favors a potential sale to the French distiller Pernod Ricardover an alternative proposal from privately-held American rival Sazerac, Bloomberg reportsThe National Security Agency is using Anthropic's advanced "Mythos Preview" model even as Department of Defense officials have labeled the company a potential supply chain risk, highlighting internal tensions over AI adoption and security concerns, Axios saysPeruvian officials looking to purchase new fighter jets concluded buying aircraft from Lockheed Martinwould be in the nation's best interest due to its price and in hopes the U.S. could become a major defense ally, Bloomberg reports4. MOVERS:Nektargained afterfrom its Phase 2b REZOLVE-AA studySila Realty Trustrose after announcing it will befor $30.38 per shareUSA Rare Earthincreased after announcing an agreement toAgiosfell after Novo NordiskreportedFermiclosed lower after announcing the exits of its CEO and CFO5. EARNINGS/GUIDANCE:Nano-X Imagingand reaffirmed its guidance for FY26Dynex Capital, with EPS missing consensusBank of Hawaii, with CEO Jim Polk commenting that the bank "began the year on firm footing"Cleveland-Cliffs, with EPS and revenue beating consensusSurf Air Mobilityreaffirmed itsINDEXES:The Dow fell 4.87, or 0.0098%, to 49,442.56, the Nasdaq lost 64.09, or 0.26%, to 24,404.39, and the S&P 500 declined 16.92, or 0.24%, to 7,109.14.
Major Averages Decline Amid Rising Tensions with Iran
The major averages were broadly lower near noon as escalating tensions with Iran, including the seizure of an Iranian-flagged cargo ship and renewed threats from President Trump, raised concerns ahead of an expiring ceasefire. Iran's refusal to participate in peace talks further heightened geopolitical uncertainty and weighed on market sentiment, though the pullback has been fairly muted so far.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:QXOTopBuildfor $17B in a cash and stock transactionEli LillyKelonia Therapeutics, with Kelonia to receive up to $7B in cashAmerican Airlinessaid it isin any merger talks with United AirlinesAST SpaceMobilewas slipping after Blue Origin's flagship New Glenn rocket failed to place one of its satellitesPresident Trump signed an executive order toto the substances used outside the U.S to treat post-traumatic stress disorder2. WALL STREET CALLS:Wells FargoBiogento Overweight on pipeline outside Alzheimer'sBarclaysAvis Budgetto sell after "sharp short squeeze"Ulta Beautyto Buy at JefferiesMizuhoQorvoto Underperform on handset weaknessOktato Overweight at Barclays3. AROUND THE WEB:Jersey Mike's Subs, Blackstone-backedsandwich chain with more than 3,000 locations, submitted a confidential filing with the U.S. Securities and Exchange Commission for its initial public offering, Bloomberg saysThe family that owns Brown-Forman, the maker of Jack Daniel's whiskey, favors a potential sale to the French distiller Pernod Ricardover an alternative proposal from privately-held American rival Sazerac, Bloomberg reportsGooglehas formed a specialized team of researchers and engineers to enhance its AI coding models, aiming to increase automation in software development and AI research, The Information saysThe National Security Agency is using Anthropic's advanced "Mythos Preview" model even as Department of Defense officials have labeled the company a potential supply chain risk, highlighting internal tensions over AI adoption and security concerns, Axios saysPeruvian officials looking to purchase new fighter jets concluded buying aircraft from Lockheed Martinwould be in the nation's best interest due to its price and in hopes the U.S. could become a major defense ally, Bloomberg reports4. MOVERS:Nektarhigher afterfrom its Phase 2b REZOLVE-AA studySila Realty Trustgains after announcing it will beaffiliates for $30.38 per shareUSA Rare Earthincreases after announcing an100% of Serra Verde GroupAgiosfalls after Novo Nordiskin sickle cell diseaseFermilower afterit was short on the company5. EARNINGS/GUIDANCE:Nano-X Imagingand reaffirmed its guidance for FY26Dynex Capital, with EPS missing consensusBank of Hawaii, with CEO Jim Polk commenting that the bank "began the year on firm footing"Cleveland-Cliffs, with EPS and revenue beating consensusSurf Air Mobility (SRFM)for FY26INDEXES:Near midday, the Dow was down 0.12%, or 57.71, to 49,389.72, the Nasdaq was down 0.68%, or 165.54, to 24,302.94, and the S&P 500 was down 0.42%, or 29.79, to 7,096.27.
Psyence Biomedical Updates Strategic Position in Global Ibogaine Market
Psyence Biomedical provided an update on its strategic position in the global ibogaine market, as regulatory and clinical interest in the compound continues to expand. Recent signals from U.S. policymakers and global health authorities reflect increasing recognition of the need for structured, evidence-based evaluation of ibogaine, particularly in areas where existing treatment options remain limited. In anticipation of this shift, Psyence BioMed has spent the past year advancing a purpose-built platform designed to support ibogaine-based programs across development and potential commercialization. Through its investment in and collaboration with PsyLabs, the Company has established an integrated supply and GMP-compliant manufacturing platform spanning sourcing at origin, extraction, purification, and pharmaceutical production. As a key operational milestone, the Company confirms it currently holds standardized, stabilized, and GMP-compliant ibogaine doses in inventory. This supply is designed to support ongoing and future research initiatives, providing immediate access to pharmaceutical-grade material and helping to reduce delays associated with supply constraints.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.